Clinical Trial Results:
A 10-day prospective, single-center, double-blind, placebo-controlled, randomized study to evaluate safety, tolerability and pharmacokinetics of 600 mg b.i.d. oral doses of LM11A-31-BHS in healthy elderly volunteers
Summary
|
|
EudraCT number |
2018-001071-20 |
Trial protocol |
ES |
Global end of trial date |
21 Mar 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Jul 2021
|
First version publication date |
07 Jul 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
NSC18001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
PharmatrophiX Inc.
|
||
Sponsor organisation address |
1015 Monte Rosa Drive, Menlo Park, CA, United States, 94025
|
||
Public contact |
CRO, NeuroScios GmbH, 0043 31324044412, nhelmberg@neuroscios.com
|
||
Scientific contact |
Frank Longo, MD, PhD, PharmatrophiX Inc., 001 6507243172, frank@pharmatrophix.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
26 Aug 2019
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
21 Mar 2019
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
21 Mar 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To investigate the safety and tolerability of 600 mg b.i.d. of LM11A-31-BHS (free base) administered orally to healthy elderly volunteers for a period of 10 days in comparison to placebo.
|
||
Protection of trial subjects |
Trial specific stopping rules were set to protect the trial subjects. Dosing would have been stopped for all subjects and the trial terminated if any of the stopping rules had occured.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
22 Jan 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 10
|
||
Worldwide total number of subjects |
10
|
||
EEA total number of subjects |
10
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
5
|
||
From 65 to 84 years |
5
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
Recruitment took place between January 22nd, 2019 and March 5th, 2019. | |||||||||
Pre-assignment
|
||||||||||
Screening details |
Screening had to be performed within three weeks prior to the baseline visit. There were 5 screening failures. | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Double blind | |||||||||
Roles blinded |
Subject, Investigator, Monitor | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
LM11A-31-BHS | |||||||||
Arm description |
600 mg LM11A-31_BHS in the morning and in the evening (total daily dosage = 1200 mg) | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
LM11A-31-BHS
|
|||||||||
Investigational medicinal product code |
LM11A-31-BHS
|
|||||||||
Other name |
||||||||||
Pharmaceutical forms |
Capsule, hard
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
3 capsules with 200 mg LM11A-31-BHS administered b.i.d. with approximately 240 mL of water
|
|||||||||
Arm title
|
Placebo | |||||||||
Arm description |
600 mg placebo in the morning and in the evening (total daily dosage = 1200 mg) | |||||||||
Arm type |
Placebo | |||||||||
Investigational medicinal product name |
Placebo
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Capsule, hard
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
3 capsules with 200 mg placebo administered b.i.d. with approximately 240 mL of water
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||
Reporting group title |
LM11A-31-BHS
|
||||||||||||||||||||||||||||||||||||||||
Reporting group description |
600 mg LM11A-31_BHS in the morning and in the evening (total daily dosage = 1200 mg) | ||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||
Reporting group description |
600 mg placebo in the morning and in the evening (total daily dosage = 1200 mg) | ||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
LM11A-31-BHS
|
||
Reporting group description |
600 mg LM11A-31_BHS in the morning and in the evening (total daily dosage = 1200 mg) | ||
Reporting group title |
Placebo
|
||
Reporting group description |
600 mg placebo in the morning and in the evening (total daily dosage = 1200 mg) |
|
||||||||||||||||||||||
End point title |
To investigate the safety and tolerability of 600 mg b.i.d. of LM11A-31-BHS administered to healthy elderly volunteers for a period of 10 days in comparison to placebo [1] | |||||||||||||||||||||
End point description |
||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
continuouse until day 11, last dose is given in the morning of day 10
|
|||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Because of the nature of the study, the results were only descriptively summerized. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
To investigate the systemic pharmacokinetics of 600 mg b.i.d. doses of LM11A-31-BHS administered orally for a period of 10 days in healthy erlderly volunteers | ||||||||||||||||||
End point description |
|||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
day 1, 2, 5, 8, 10 and 11 with several timepoints on day 1 and 10
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
To evaluate cerebrospinal fluid (CSF) levels of LM11A-31-BHS under the conditions of this trial | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
several timepoints on day 10
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
January 22nd, 2019 - March 21st, 2019
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
LM11A-31-BHS
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |